Report overview
IgA nephropathy, also known as Berger's disease, is?a kidney disease that occurs when IgA deposits build up in the kidneys, causing inflammation that damages kidney tissues. IgA is an antibody?a protein made by the immune system to protect the body from foreign substances such as bacteria or viruses.
This report aims to provide a comprehensive presentation of the global market for IgA Nephropathy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding IgA Nephropathy Drugs. This report contains market size and forecasts of IgA Nephropathy Drugs in global, including the following market information:
Global IgA Nephropathy Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global IgA Nephropathy Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Phase I Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of IgA Nephropathy Drugs include Calliditas Therapeutics, Travere Therapeutics, Omeros Corporation, Novartis International, Chinook Therapeutics, Vera Therapeutics and Otsuka Pharmaceutical, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the IgA Nephropathy Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global IgA Nephropathy Drugs Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global IgA Nephropathy Drugs Market Segment Percentages, by Type, 2022 (%)
Phase I
Phase II
Phase III
Global IgA Nephropathy Drugs Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global IgA Nephropathy Drugs Market Segment Percentages, by Application, 2022 (%)
Clinical Treatment
Drug Experiment
Global IgA Nephropathy Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global IgA Nephropathy Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies IgA Nephropathy Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies IgA Nephropathy Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Calliditas Therapeutics
Travere Therapeutics
Omeros Corporation
Novartis International
Chinook Therapeutics
Vera Therapeutics
Otsuka Pharmaceutical
Outline of Major Chapters:
Chapter 1: Introduces the definition of IgA Nephropathy Drugs, market overview.
Chapter 2: Global IgA Nephropathy Drugs market size in revenue.
Chapter 3: Detailed analysis of IgA Nephropathy Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of IgA Nephropathy Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
